Securities Report – 112th Fiscal Period (2025/04/01 – 2026/03/31)

Kokando Co., Ltd. Securities Report – 112th Fiscal Period (2025/04/01 – 2026/03/31)

This report is the Securities Report submitted by Kokando Co., Ltd. (hereinafter referred to as "the Company") pursuant to the Financial Instruments and Exchange Act, covering the Company's business performance, financial condition, and management policies for the 112th fiscal period (from April 1, 2025 to March 31, 2026).

The Company's primary business activities include the manufacturing and sales of pharmaceuticals, medical devices, and health foods. Since its establishment, the Company has integrated the knowledge of Kampo medicine with modern scientific technology, striving to develop and supply safe and reliable products.

This report provides detailed disclosures on the Company's financial statements, business overview, future outlook, risk factors, and corporate governance. These materials serve as essential references for shareholders, investors, financial institutions, and other stakeholders in evaluating the Company's corporate value.

Going forward, the Company will continue to maintain transparent information disclosure and strive for sustainable growth and enhancement of corporate value.